Fast Five Quiz: Type 2 Diabetes and Dyslipidemia

Anne L. Peters, MD; Romesh Khardori, MD, PhD


April 21, 2023

Patients with type 2 diabetes and established CVD are at very high risk for major adverse cardiovascular events. For patients with type 2 diabetes and ASCVD who require additional lowering of LDL cholesterol despite the maximally tolerated dose of statins and cholesterol absorption inhibitor, such as ezetimibe, the American College of Cardiology and European Society of Cardiology recommend the addition of a PCSK9 inhibitor. These recommendations were made after the FOURIER clinical trial demonstrated that patients taking evolocumab were at a significantly lower risk compared with placebo for cardiovascular events: stroke, myocardial infarction, and coronary revascularization. In addition, evolocumab was shown to reduce cholesterol by 59%.

Icosapent ethyl may be an option to lower triglycerides in patients being treated with statin therapy. In randomized trials, icosapent ethyl was demonstrated to improve the risk for subsequent ischemic events in patients with a history of prior percutaneous coronary intervention.

Learn more about type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.